Prognostic factors for response at the time of starting treatment with tafasitamab / lenalidomide
| At Tafasitamab-Lenalidomide . | ORR (%) . | CRR (%) . | CR/PR/SD (%) . | |||
|---|---|---|---|---|---|---|
| Cohort . | ITT (n=99) . | Efficacy (n=83) . | ITT (n=99) . | Efficacy (n=83) . | ITT (n=99) . | Efficacy (n=83) . |
| Age: | P=0.75 | P=0.98 | P=1 | P=1 | P=0.54 | P=0.86 |
| 18-60 years | 5 (45%) | 5 (56%) | 4 (36%) | 4 (44%) | 5 (45%) | 5 (56%) |
| >60 years | 46 (52%) | 46 (62%) | 31 (35%) | 31 (42%) | 49 (56%) | 48 (65%) |
| Doble-hit HGL: | P=0.18 | P=0.14 | P=0.58 | P=0.57 | P=0.13 | P=0.10 |
| Yes | 1 (17%) | 1 (20%) | 1 (17%) | 1 (20%) | 1 (17%) | 1 (20%) |
| No | 50 (54%) | 50 (64%) | 34 (37%) | 34 (44%) | 53 (57%) | 52 (67%) |
| ECOG PS: | P=0.025 | P=0.24 | P=0.009 | P=0.057 | P=0.063 | P=0.33 |
| 0-1 | 37 (61%) | 37 (66%) | 28 (46%) | 28 (50%) | 38 (62%) | 38 (67%) |
| 2-4 | 14 (37%) | 14 (52%) | 7 (18%) | 7 (26%) | 16 (42%) | 15 (56%) |
| AA stage: | P=0.67 | P=1 | P=0.37 | P=0.48 | P=0.39 | P=0.81 |
| I-II | 17 (55%) | 17 (63%) | 13 (42%) | 13 (48%) | 19 (61%) | 18 (67%) |
| III-IV | 34 (50%) | 34 (61%) | 22 (32%) | 22 (39%) | 35 (51%) | 35 (62%) |
| LDH: | P=0.29 | P=1 | P=0.029 | P=0.11 | P=0.14 | P=0.64 |
| Normal | 24 (60%) | 24 (63%) | 20 (50%) | 20 (53%) | 26 (65%) | 26 (68%) |
| Elevated | 25 (47%) | 25 (61%) | 14 (26%) | 14 (34%) | 26 (49%) | 25 (61%) |
| R-IPI: | P=0.22 | P=1 | P=0.018 | P=0.13 | P=0.10 | P=0.65 |
| 0-2 | 24 (60%) | 24 (61%) | 20 (50%) | 20 (51%) | 26 (65%) | 26 (67%) |
| 3-5 | 27 (46%) | 27 (61%) | 15 (25%) | 15 (34%) | 28 (47%) | 27 (61%) |
| CIRS: | P=0.83 | P=0.48 | P=0.83 | P=0.64 | P=1 | P=0.81 |
| 0-6 | 25 (50%) | 25 (57%) | 18 (36%) | 18 (41%) | 28 (56%) | 27 (61%) |
| >6 | 21 (54%) | 21 (66%) | 15 (38%) | 15 (47%) | 21 (54%) | 21 (66%) |
| Previous lines: | P=0.18 | P=0.21 | P=0.48 | P=0.62 | P=0.073 | P=0.13 |
| 1-2 | 40 (56%) | 40 (66%) | 27 (38%) | 27 (44%) | 43 (61%) | 42 (69%) |
| >2 | 11 (39%) | 11 (50%) | 8 (29%) | 8 (36%) | 11 (39%) | 11 (50%) |
| Previous line response: | P=0.004 | P=0.023 | P=0.001 | P=0.007 | P<0.001 | P=0.021 |
| Relapse | 28 (70%) | 28 (76%) | 22 (55%) | 22 (59%) | 30 (75%) | 29 (78%) |
| Refractory/progression | 23 (39%) | 23 (50%) | 13 (22%) | 13 (28%) | 24 (41%) | 24 (52%) |
| Primary refractory: | P=0.061 | P=0.36 | P=0.004 | P=0.025 | P=0.021 | P=0.25 |
| Yes | 27 (43%) | 27 (56%) | 15 (24%) | 15 (31%) | 28 (45%) | 28 (58%) |
| No | 24 (65%) | 24 (69%) | 20 (54%) | 20 (57%) | 26 (70%) | 25 (71%) |
| L-MIND eligible: | P=0.35 | P=1 | P=0.080 | P=0.21 | P=0.34 | P=1 |
| Yes | 14 (61%) | 14 (64%) | 12 (52%) | 12 (54%) | 15 (65%) | 14 (64%) |
| No | 37 (49%) | 37 (61%) | 23 (30%) | 23 (38%) | 39 (51%) | 39 (64%) |
| At Tafasitamab-Lenalidomide . | ORR (%) . | CRR (%) . | CR/PR/SD (%) . | |||
|---|---|---|---|---|---|---|
| Cohort . | ITT (n=99) . | Efficacy (n=83) . | ITT (n=99) . | Efficacy (n=83) . | ITT (n=99) . | Efficacy (n=83) . |
| Age: | P=0.75 | P=0.98 | P=1 | P=1 | P=0.54 | P=0.86 |
| 18-60 years | 5 (45%) | 5 (56%) | 4 (36%) | 4 (44%) | 5 (45%) | 5 (56%) |
| >60 years | 46 (52%) | 46 (62%) | 31 (35%) | 31 (42%) | 49 (56%) | 48 (65%) |
| Doble-hit HGL: | P=0.18 | P=0.14 | P=0.58 | P=0.57 | P=0.13 | P=0.10 |
| Yes | 1 (17%) | 1 (20%) | 1 (17%) | 1 (20%) | 1 (17%) | 1 (20%) |
| No | 50 (54%) | 50 (64%) | 34 (37%) | 34 (44%) | 53 (57%) | 52 (67%) |
| ECOG PS: | P=0.025 | P=0.24 | P=0.009 | P=0.057 | P=0.063 | P=0.33 |
| 0-1 | 37 (61%) | 37 (66%) | 28 (46%) | 28 (50%) | 38 (62%) | 38 (67%) |
| 2-4 | 14 (37%) | 14 (52%) | 7 (18%) | 7 (26%) | 16 (42%) | 15 (56%) |
| AA stage: | P=0.67 | P=1 | P=0.37 | P=0.48 | P=0.39 | P=0.81 |
| I-II | 17 (55%) | 17 (63%) | 13 (42%) | 13 (48%) | 19 (61%) | 18 (67%) |
| III-IV | 34 (50%) | 34 (61%) | 22 (32%) | 22 (39%) | 35 (51%) | 35 (62%) |
| LDH: | P=0.29 | P=1 | P=0.029 | P=0.11 | P=0.14 | P=0.64 |
| Normal | 24 (60%) | 24 (63%) | 20 (50%) | 20 (53%) | 26 (65%) | 26 (68%) |
| Elevated | 25 (47%) | 25 (61%) | 14 (26%) | 14 (34%) | 26 (49%) | 25 (61%) |
| R-IPI: | P=0.22 | P=1 | P=0.018 | P=0.13 | P=0.10 | P=0.65 |
| 0-2 | 24 (60%) | 24 (61%) | 20 (50%) | 20 (51%) | 26 (65%) | 26 (67%) |
| 3-5 | 27 (46%) | 27 (61%) | 15 (25%) | 15 (34%) | 28 (47%) | 27 (61%) |
| CIRS: | P=0.83 | P=0.48 | P=0.83 | P=0.64 | P=1 | P=0.81 |
| 0-6 | 25 (50%) | 25 (57%) | 18 (36%) | 18 (41%) | 28 (56%) | 27 (61%) |
| >6 | 21 (54%) | 21 (66%) | 15 (38%) | 15 (47%) | 21 (54%) | 21 (66%) |
| Previous lines: | P=0.18 | P=0.21 | P=0.48 | P=0.62 | P=0.073 | P=0.13 |
| 1-2 | 40 (56%) | 40 (66%) | 27 (38%) | 27 (44%) | 43 (61%) | 42 (69%) |
| >2 | 11 (39%) | 11 (50%) | 8 (29%) | 8 (36%) | 11 (39%) | 11 (50%) |
| Previous line response: | P=0.004 | P=0.023 | P=0.001 | P=0.007 | P<0.001 | P=0.021 |
| Relapse | 28 (70%) | 28 (76%) | 22 (55%) | 22 (59%) | 30 (75%) | 29 (78%) |
| Refractory/progression | 23 (39%) | 23 (50%) | 13 (22%) | 13 (28%) | 24 (41%) | 24 (52%) |
| Primary refractory: | P=0.061 | P=0.36 | P=0.004 | P=0.025 | P=0.021 | P=0.25 |
| Yes | 27 (43%) | 27 (56%) | 15 (24%) | 15 (31%) | 28 (45%) | 28 (58%) |
| No | 24 (65%) | 24 (69%) | 20 (54%) | 20 (57%) | 26 (70%) | 25 (71%) |
| L-MIND eligible: | P=0.35 | P=1 | P=0.080 | P=0.21 | P=0.34 | P=1 |
| Yes | 14 (61%) | 14 (64%) | 12 (52%) | 12 (54%) | 15 (65%) | 14 (64%) |
| No | 37 (49%) | 37 (61%) | 23 (30%) | 23 (38%) | 39 (51%) | 39 (64%) |
Abbreviations: ITT: intend-to-treat; ORR: overall response rate; CRR: complete response rate; DCR: duration of complete response; 95%CI: 95% confidence interval; CR: complete response; PR: partial response; SD: stable disease; HGL: high-grade lymphoma; ECOG: Eastern cooperative oncology group; PS: performance status; AA: Ann Arbor; LDH: lactate dehydrogenase; R-IPI: revised International Prognostic Index; CIRS: cumulative illness rating scale.